全文获取类型
收费全文 | 90283篇 |
免费 | 6050篇 |
国内免费 | 2444篇 |
专业分类
耳鼻咽喉 | 125篇 |
儿科学 | 852篇 |
妇产科学 | 1286篇 |
基础医学 | 6770篇 |
口腔科学 | 926篇 |
临床医学 | 9087篇 |
内科学 | 8945篇 |
皮肤病学 | 804篇 |
神经病学 | 4275篇 |
特种医学 | 1153篇 |
外国民族医学 | 3篇 |
外科学 | 4616篇 |
综合类 | 4088篇 |
现状与发展 | 4篇 |
一般理论 | 23篇 |
预防医学 | 5626篇 |
眼科学 | 468篇 |
药学 | 38549篇 |
12篇 | |
中国医学 | 7456篇 |
肿瘤学 | 3709篇 |
出版年
2024年 | 267篇 |
2023年 | 3086篇 |
2022年 | 4710篇 |
2021年 | 4715篇 |
2020年 | 5034篇 |
2019年 | 3346篇 |
2018年 | 3406篇 |
2017年 | 3707篇 |
2016年 | 3928篇 |
2015年 | 3856篇 |
2014年 | 6653篇 |
2013年 | 5717篇 |
2012年 | 5463篇 |
2011年 | 4956篇 |
2010年 | 4537篇 |
2009年 | 4034篇 |
2008年 | 3006篇 |
2007年 | 3333篇 |
2006年 | 2702篇 |
2005年 | 2131篇 |
2004年 | 1796篇 |
2003年 | 1593篇 |
2002年 | 1719篇 |
2001年 | 1525篇 |
2000年 | 1312篇 |
1999年 | 1417篇 |
1998年 | 878篇 |
1997年 | 719篇 |
1996年 | 747篇 |
1995年 | 676篇 |
1994年 | 551篇 |
1993年 | 483篇 |
1992年 | 802篇 |
1991年 | 818篇 |
1990年 | 796篇 |
1989年 | 650篇 |
1988年 | 709篇 |
1987年 | 494篇 |
1986年 | 339篇 |
1985年 | 271篇 |
1984年 | 372篇 |
1983年 | 225篇 |
1982年 | 199篇 |
1981年 | 204篇 |
1980年 | 178篇 |
1979年 | 138篇 |
1978年 | 105篇 |
1977年 | 98篇 |
1976年 | 80篇 |
1974年 | 76篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
目的 系统评价中药治疗哮喘-慢阻肺(ACO)的疗效与安全性。方法 全面检索PubMed、Cochrane Library、Web of Science、中国知网、万方、维普、中国医学文献数据库,纳入有关中医药治疗ACO的随机对照试验(RCT),运用Cochrane手册对纳入研究的方法学质量进行评估,采用Review Manager 5.3进行Meta分析。结果 共纳入32项RCT,包括2688例ACO患者,其中试验组1361例,对照组1327例。Meta分析结果显示,中医药可以显著改善ACO患者的中医证候疗效[RR=1.19,95% CI(1.13,1.25),P<0.00001]、CAT评分[MD=-3.62,95% CI(-4.37,-2.87),P<0.00001]、ACT评分[MD=3.42,95% CI(2.23,4.62),P<0.00001],、中医证候总积分[MD=-3.61,95% CI(-4.83,-2.39),P<0.00001]、FEV1[MD=0.59,95% CI(0.08,1.10),P=0.02]、FEV1%[MD=8.61,95% CI(5.20,12.1),P<0.00001]、FEV1/FVC[MD=6.52,95% CI(4.24,8.80),P<0.00001]、6 min步行实验[MD=41.18,95% CI(22.15,60.21),P<0.0001]、急性发作次数[MD=-2.46,95% CI(-3.62,-1.13),P<0.0001]。所有研究均未报道严重不良反应。结论 中药治疗ACO,可以显著提高临床疗效,改善患者的肺功能且具有较好安全性,但是需要更高质量、多样本、多中心的随机对照试验进一步确认。 相似文献
32.
《Journal of pharmaceutical sciences》2022,111(11):3029-3037
This study aimed to characterize a stable nano-niosome formulation, which could reduce the adverse effects of carboplatin (CB) and improve its therapeutic efficacy in the treatment of breast cancer. For this purpose, CB-loaded polyethylene glycol (PEG)ylated niosome nanoparticles (PEG-NS-CB) were synthesized using the reverse-phase evaporation method. PEG-NS-CB (226.0 ± 10.6 nm) could release CB in a controlled manner and, compared to CB and CB-loaded non-PEGylated niosome (NS-CB), caused higher cytotoxicity effects against mouse breast cancer 4T1 cells (IC50: 83.4, 26.6, and 22.5 µM for CB, NS-CB, and PEG-NS-CB, respectively). Also, PEG-NS-CB demonstrated higher stability, in which its profile of drug release, cytotoxicity, and LE% did not change significantly three months after preparation compared to those at the production time. In addition, the in vivo results demonstrated that PEG-NS-CB caused higher therapeutic (the number of alive mice: 12, 15, and 17 out of 20 in CB, NS-CB, and PEG-NS-CB receiver groups, respectively) and less toxicity effects (weight loss of 17, 12.5, and 10% in CB, NS-CB, and PEG-NS-CB receiver groups, respectively), compared to NS-CB and CB in breast cancer-bearing mice. Overall, the results of this study suggest that PEG-NS-CB could be a promising formulation for the treatment of breast cancer. 相似文献
33.
34.
《Clinical therapeutics》2022,44(2):193-214.e1
PurposeThe goal of this study was to review the role of human milk in shaping the infant intestinal microbiota and the potential of human milk bioactive molecules to reverse trends of increasing intestinal dysbiosis and dysbiosis-associated diseases.MethodsThis narrative review was based on recent and historic literature.FindingsHuman milk immunoglobulins, oligosaccharides, lactoferrin, lysozyme, milk fat globule membranes, and bile salt–stimulating lipase are complex multifunctional bioactive molecules that, among other important functions, shape the composition of the infant intestinal microbiota.ImplicationsThe co-evolution of human milk components and human milk–consuming commensal anaerobes many thousands of years ago resulted in a stable low-diversity infant microbiota. Over the past century, the introduction of antibiotics and modern hygiene practices plus changes in the care of newborns have led to significant alterations in the intestinal microbiota, with associated increases in risk of dysbiosis-associated disease. A better understanding of mechanisms by which human milk shapes the intestinal microbiota of the infant during a vulnerable period of development of the immune system is needed to alter the current trajectory and decrease intestinal dysbiosis and associated diseases. 相似文献
35.
《Saudi Pharmaceutical Journal》2022,30(1):91-101
Emerging evidence has shown that the therapy-induced senescent growth arrest in cancer cells is of durable nature whereby a subset of cells can reinstate proliferative capacity. Promising new drugs named senolytics selectively target senescent cells and commit them into apoptosis. Accordingly, senolytics have been proposed as adjuvant cancer treatment to cull senescent tumor cells, and thus, screening for agents that exhibit senolytic properties is highly warranted. Our study aimed to investigate three agents, sorafenib, rapamycin, and venetoclax for their senolytic potential in doxorubicin-induced senescence in HCT116 cells. HCT116 cells were treated with one of the three agents, sorafenib (5 µM), rapamycin (100 nM), or venetoclax (10 µM), in the absence or presence of doxorubicin (1 µM). Senescence was evaluated using microscopy-based and flow cytometry-based Senescence-associated-β-galactosidase staining (SA-β-gal), while apoptosis was assessed using annexin V-FITC/PI, and Muse caspase-3/-7 activity assays. We screened for potential genes through which the three drugs exerted senolytic-like action using the Human Cancer Pathway Finder PCR array. The three agents reduced doxorubicin-induced senescent cell subpopulations and significantly enhanced the apoptotic effect of doxorubicin compared with those treated only with doxorubicin. The senescence genes IGFBP5 and BMI1 and the apoptosis genes CASP7 and CASP9 emerged as candidate genes through which the three drugs exhibited senolytic-like properties. These results suggest that the attenuation of doxorubicin-induced senescence might have shifted HCT116 cells to apoptosis by exposure to the tested pharmacological agents. Our work argues for the use of senolytics to reduce senescence-mediated resistance in tumor cells and to enhance chemotherapy efficacy. 相似文献
36.
37.
Toxicity resulting from off-target effects, beyond acetylcholine esterase inhibition, for the commonly used organophosphate (OP) insecticides chlorpyrifos (CPS) and malathion (MA) was investigated using Saccharomyces cerevisiae and Caenorhabditis elegans model systems. Mitochondrial damage and dysfunction were observed in yeast following exposure to CPS and MA, suggesting this organelle is a major target. In the C. elegans model, the mitochondrial unfolded protein response pathway showed the most robust induction from CPS and MA treatment among stress responses examined. GABAergic neurodegeneration was observed with CPS and MA exposure. Impaired movement observed in C. elegans exposed to CPS and MA may be the result of motor neuron damage. Our analysis suggests that stress from CPS and MA results in mitochondrial dysfunction, with GABAergic neurons sensitized to these effects. These findings may aid in the understanding of toxicity from CPS and MA from high concentration exposure leading to insecticide poisoning. 相似文献
38.
39.
《Clinical colorectal cancer》2022,21(2):e145-e147
Introduction: The aim of this analysis is to assess the pharmacological costs of trifluridine/tipiracil as first-line treatment in metastatic colorectal cancer (mCRC) patients who were not candidates for combination with cytotoxic chemotherapies.Discussion: TASCO1 Trial was considered (153 patients). Differences in costs between the 2 arms (trifluridine/tipiracil plus bevacizumab vs. capecitabine plus bevacizumab) was 9113 € (10 264 USD), with a cost savings of 1982 € (2232 USD) per month of overall survival (OS)-gain.Conclusion: Trifluridine/tipiracil could be consider a cost-effective treatment also in first-line for mCRC patients who were not candidates for combination with cytotoxic chemotherapies. 相似文献
40.